key: cord-0960779-p9lugd44 authors: Huang, Mao; Yang, Yi; Shang, Futai; Zheng, Yishan; Zhao, Wenjing; Luo, Liang; Han, Xudong; Lin, Aihua; Zhao, Hongsheng; Gu, Qing; Shi, Yi; Li, Jun; Xu, Xingxiang; Liu, Kexi; Deng, YiJun; Cao, Quan; Wang, Weiwei title: Clinical Characteristics and Predictors of Disease Progression in Severe Patients with COVID-19 Infection in Jiangsu Province, China: A Descriptive Study date: 2020-06-01 journal: Am J Med Sci DOI: 10.1016/j.amjms.2020.05.038 sha: 6b829d5b77ab8a7ed187dafc6d996101ae7397d2 doc_id: 960779 cord_uid: p9lugd44 BACKGROUND: We studied patients with coronavirus disease 2019 (COVID-19) infected by severe acute respiratory syndrome coronavirus 2, a virus that originated in Wuhan, China, and is spreading over the country including Jiangsu Province. We studied the clinical characteristics and therapies of severe cases in Jiangsu Province. METHODS: A multicenter retrospective cohort study was conducted to analyze clinical, laboratory data and treatment of 60 severe cases with COVID-19 infection in Jiangsu Province between January 24, 2020 and April 20, 2020. The improvement and deterioration subgroups were compared to identify predictors of disease progression. RESULTS: A total of 653 infected cases with COVID-19 were reported in Jiangsu Province, of which 60 severe cases were included in this study. Up until April 20, 2020, the mortality of severe patients was 0%. The median age was 57 years. The average body mass index of these patients was 25 kg/m². White blood cell counts decreased in 45.0% of patients, lymphopenia in 63.3%, thrombocytopenia in 13.3% and procalcitonin levels in 88.3% of the patients were less than 0.5 ng/mL. There were no statistically significant differences in immunoglobulin therapy and GCs therapy between the improvement and deterioration subgroups. Logistic regression analysis identified higher levels of troponin T (odds ratio [OR]: 1.04; 95% confidence interval [CI]: 1.00-1.08; P = 0.04), antiviral therapy with aerosol inhalation of interferon (OR: 6.33; 95% CI: 1.18-33.98; P = 0.03), and the application of non-invasive mechanical ventilation (OR: 1.99; 95%CI: 1.17-3.41; P = 0.01) as predictors of disease progression, whereas higher lymphocyte count (OR: 0.11; 95% CI: 0.02-0.57; P = 0.01) and early prone ventilation were associated with improvement (OR: 0.11; 95% CI: 0.01-0.98; P = 0.04). CONCLUSIONS: COVID-19 infection had a low mortality rate in Jiangsu Province, China. The higher levels of troponin T and lower lymphocyte count were predictors of disease progression. Early prone ventilation may be an effective treatment for severe cases. T he coronavirus disease 2019 (COVID-19) is a novel highly contagious disease first reported from Wuhan, Hubei Province, China on Dec 8, 2019 and then rapidly spread globally by human-tohuman transmission. Severe cases could cause difficulty breathing and acute respiratory distress syndrome. 1, 2 Increasing confirmed cases and deaths pose huge challenges to public health and governance. 3 Cases have now spread to at least 6 continents. 4, 5 As of April 20, 2020, there were more than 84,237 cases with laboratory-confirmed COVID-19 infection, and over 4,642 deaths in China. 6 In addition, more than 2,326,435 cases had been confirmed and 161,293 deaths in more than 100 countries, including America, Italy, Spanish, France, Germany, England and so on. [7] [8] [9] [10] [11] At present, several publications have described the epidemiological characteristics, clinical manifestations, clinical prognosis, genomic characteristics and antiviral treatment of cases with COVID-19 infection. 9, [12] [13] [14] [15] [16] The clinical spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia varies in different studies. In some patients, the disease changed rapidly and could quickly develop into progressive pneumonia, respiratory failure, and even death. 17, 18 However, the clinical characteristics and systematic review of treatment for COVID-19 infected patients in critical condition have rarely been reported. Up to April 20, 2020, a total of 653 cases were confirmed in Jiangsu Province, including 60 severe cases admitted to intensive care units (ICU). Although the epidemic occurred relatively late in Jiangsu, as an infectious disease, patients with COVID-19 had to come to the hospital as soon as possible and receive early diagnosis and treatment. Our aim was to study the epidemiological, clinical, laboratory and radiological characteristics, treatment regimens and clinical outcomes of severe patients diagnosed with COVID-19 infection in Jiangsu Province, China. We hope that our findings can provide some reference experience and theoretical basis for the treatment of severe cases of COVID-19 infection in the global community. Since December 8, 2019, the COVID-19 originated in Wuhan, Hubei Province and had spread rapidly to almost all provinces and cities in China, including Jiangsu Province. For this multicenter retrospective cohort study, we recruited confirmed patients with COVID-19 infection between January 24 and April 20, 2020, from 12 hospitals in Jiangsu Province, China, and described in detail the 60 severe cases. The patients' medical records were sent to Nanjing, where data collection and analysis were coordinated by the Health Department of Jiangsu Province. 19 The research was approved by the institutional ethics board of the First Affiliated Hospital of Nanjing Medical University. Written informed consent was waived in view of the urgent need to collect clinical data. Information recorded included demographics (including age, sex, body mass index [BMI] and exposure history), symptoms, underlying diseases, complications, incubation period, APACHE II score 20 on admission, laboratory and chest radiographs findings prior to and during treatment. Treatment variables included antiviral therapy, antibiotic therapy, means of oxygen support, early prone position ventilation, the use of glucocorticoids (GCs), intravenous immunoglobulin therapy, and negative fluid balance. Clinical outcomes were followed up until April 20, 2020. If the records were missing or needed to be clarified, we obtained the data through direct communication with the attending physicians and other health care providers. The data was reviewed by a trained team of physicians. The main end points were significant improvement or discharge, or deterioration by April 20, 2020. Since clinical observations are still ongoing and no patients have died, no fixed time horizon has been applied to these endpoints. Throat-swabs or endotracheal specimens taken from suspected cases were sent to the Jiangsu Center for Disease Control and Prevention. 19 After the initial detection of respiratory pathogens, samples were sent to the Chinese Center for Disease Prevention and Control (CDC). Laboratory confirmation of the 2019-nCoV was performed by the real-time reverse transcription polymerase chain reaction (RT-PCR) assays in accordance with the protocol established by the World Health Organization (WHO). 15 The following terms were defined prior to data analysis. The definitions of suspected and confirmed cases of COVID-19 infection were based on the Diagnosis and Treatment of Pneumonia Caused by Novel Coronavirus (Pilot Version 5) 23 issued by the National health and fitness commission of China. Similarly, mild and severe patients were classified according to the above newly issued diagnostic criteria. Patients with mild symptoms were described as having no or only mild clinical and radiological manifestations. Severe patients were defined as obvious respiratory distress (respiratory rate greater than 30 breaths per minute), hypoxemia (oxygen saturation less than 93% or oxygenation index no more than 300 mmHg), and even respiratory failure being required to be admitted to ICU. In severe patients, oxygen support referred to high flow nasal cannula (HFNC), non-invasive mechanical ventilation, invasive mechanical ventilation or early prone position ventilation. The oxygenation index was calculated by dividing the partial pressure of arterial oxygen (PaO₂) by the inspiratory oxygen fraction (FiO₂), and the normal value was between 400 and 500 mmHg. 24 The definition of acute respiratory distress syndrome (ARDS) referred to the Berlin diagnostic criteria. 25 Clinical outcomes included discharge from hospital, improvement, and deterioration. Improvement was defined as PaO₂/FiO₂ ratio greater than 300 mmHg or transferred from ICU to a general ward after treatment. 23 Similarly, according to the fifth edition of the guidelines, 23 deterioration was defined as a significant decrease in a patient's PaO₂/FiO₂ ratio, and the need for invasive mechanical ventilation, or the onset of shock, or combined with other organs failure. Continuous variables were compared with Student t test (for normally distributed variables) or the Mann-Whitney U test (for non-normally distributed variables). Categorical variables were evaluated with the x2 or 2-tailed Fisher exact test. Results are expressed as mean § standard deviation (SD) or median (range; continuous variables) or as percentages of the group from which they were derived (categorical variables). Twotailed tests were used to determine statistical significance; a value of P less than 0.05 was considered significant. 26 Univariate analysis and logistic regression were used to identify risk factors for disease deterioration. All statistical analyses were performed with the SPSS, version 20.0. By April 20, 2020, 84,237 symptomatic patients had been confirmed with the COVID-19 infection in China, of which 653 confirmed patients in Jiangsu Province, China. Further study and analysis were conducted on 60 severe cases of 653 confirmed patients from 12 hospitals in Jiangsu Province ( Figure 1 ). The demographic and clinical characteristics are shown in Table 1 . The 60 confirmed severe cases were positive by real-time reverse transcription polymerase chain reaction (RT-PCR) test of secretions from throat swabs. 35 (58.3%) were male; the median age of the patients was 57 years (range, 26-97 years); the proportion of patients over the age of 50 was 63.3%, higher than that of patients under the age of 50. The mean BMI of the severe patients was 25 § 3.3 kg/m 2 . A history of contact with people from Wuhan, contact with a confirmed patient, staying in the same train compartment with the patient, and dining together was documented in 41.7%, 16.7%, 5.0% and 3.3% of patients, respectively. 3.3% were healthcare workers. 30.0% were family cluster. The mean incubation period for these patients was 7.7 § 3.9 days. Fever (80.0%) and dry cough (51.7%) were the most common symptoms, whereas expectoration (5.0%), vomiting (3.3%) and chest pain (1.7%) were rare. Among the patients with fever, patients with a temperature above 38.5 accounted for 6.7%, significantly less than those with a temperature below 38.5. Thirty-one patients (51.7%) had at least 1 preexisting condition (i.e., hypertension, diabetes, autoimmune disease, stroke), including 1 pregnancy. Mean APACHE II score at admission were 14 § 5 scores. Table 2 showed the radiologic and laboratory findings of these 60 severe cases on admission. White blood cell counts were normal in 30 patients (50.0%) and decreased in 27 patients (45.0%); 38 patients (63.3%) had lymphopenia. Thrombocytopenia occurred in 8 patients (13.3%). The procalcitonin levels were less than 0.5 ng/mL in 53 (88.3%) of the patients. The average level of albumin for these patients was 34.7 § 5.1 g/L. Lactate dehydrogenase was elevated in 48 patients (80%) patients; elevated levels of alanine aminotransferase (>50 U/L) and aspartate aminotransferase (>40 U/L) were present in 60% or more of patients. The increase of creatine kinase, creatine kinase isoenzyme and troponin T was documented in 30.0%, 26.7% and 31.7% of patients, respectively. All patients had abnormal imaging presentations consistent with pneumonia. The most common pattern of chest CT was bilateral patchy shadows (85.0%). Figure 2 shows the representative radiologic findings of a severe patient at the early and deterioration stages of disease. A total of 9 patients (15.0%) developed ARDS after admission and 16 patients (26.7%) developed respiratory failure (Table 3) . Secondary bacterial or fungal infections occurred in 4 patients (6.7%). Acute liver injury, defined by alanine aminotransferase greater than 50 U/L or aspartate aminotransferase greater than 40 U/L, was observed in 41 patients (68.3%). All patients received antiviral therapy. Abidor was given to 50 patients (83.3%), lopinavir and ritonavir to 41 (68.3%), aerosol inhalation of interferon to 12 (20.0%), ribavirin to 7 (11.7%) and oseltamivir to 2 (3.3%). The mean course of antiviral was 10.9 § 4.2 days. In addition, 56 patients (93.3%) were treated with antibiotics, of which fluoroquinolones (61.7%) was the most commonly used antibiotics. Thirty-four patients (56.7%), which had higher serum levels of interleukin-1 and interleukin-6, received intravenous glucocorticoid administration at doses ranging from 40-80mg/d. Twenty-eight patients (46.7%) received immunoglobulin (IgG enriched) injections for a period of 5-9 days immunoregulation. In addition, 20 patients (33.3%) were treated with negative fluid balance therapy. For respiratory support, 14 patients (23.3%) received the noninvasive mechanical ventilation, 15 (25.0%) received high-flow nasal cannula (HFNC) therapy, and 6 (10.0%) received a combination of the above. Three patients (5.0%) were treated with invasive mechanical ventilation with tidal volumes of 4-7 mL/kg predicted body weight in accordance with lung protective ventilation strategy. 27 In the invasive or noninvasive respiratory support, 29 patients (48.3%) were given early prone ventilation. The average time from admission to noninvasive mechanical ventilation was 3.5 § 3.8 days. In addition, 2 patients received continuous renal replacement therapy (CRRT) and 1 received extracorporeal membrane oxygenation (ECMO). As of Apr 20, 2020, no patients had died, 50 patients had significantly improved, 2 patients had been discharged and 8 patients were still in serious conditions. The clinical outcomes are shown in the last section of Table 3 . Based on the clinical outcome, patients were assigned to an improvement group and deterioration group for further analysis. Univariate analysis revealed significant differences between the patients who had improved and patients with aggravated conditions subgroups. Patients in the latter group were more likely to have lower lymphocyte count, higher levels of troponin T, and antiviral therapy with aerosol inhalation of interferon. Also, this group had lower rates of application of early prone ventilation and higher rates of non-invasive mechanical ventilation. There were no statistically significant differences between the 2 groups in BMI, preexisting conditions, APACHE II score, white blood cell count, platelet count, administration of glucocorticoid, immunoglobulin therapy, negative fluid balance, or HFNC (All P>0.05). Logistic regression analysis showed higher levels of troponin T (OR: 1.04; 95% CI: 1.00-1.08; P = 0.04), antiviral therapy with aerosol inhalation of interferon (OR: 6.33; 95% CI: 1.18-33.98; P = 0.03), and the application of non-invasive mechanical ventilation (OR: 1.99; 95%CI: 1.17-3.41; P = 0.01) as predictors of disease progression, whereas higher lymphocyte count (OR: 0.11; 95% CI: 0.02-0.57; P = 0.01) and early prone ventilation were associated with improvement (OR: 0.11; 95% CI: 0.01-0.98; P = 0.04; Table 4 ). After the application of early prone position ventilation, the change trend of patients' oxygenation index (PaO₂/FiO₂ ratio) on the first, third, fifth and seventh days were shown in Figure 3 . It was found that the oxygenation index of severe patients improved after the application of early prone position ventilation. The study presented a cohort of 60 severe patients of COVID-19 in Jiangsu Province, China. The overall mortality rate in Jiangsu Province was 0% by Apr 20, 2020. There were 86.7% of severe patients improved or were discharged from hospital, suggesting that the COVID-19 had been effectively controlled and treated in Jiangsu Province. There was no significant difference between males and females in these severe cases. The median age of the patients was 57 years, and the proportion of patients over the age of 50 was 63.3%. The age distribution was similar to seasonal influenza. 28 The mean BMI of the severe patients was 25 § 3.3 kg/m 2 , which was overweight. More than 90 percent of the patients had a history of contact with an infected patient or dined together, and 2 patients were infected while staying in the same train compartment with a confirmed patient. Our study provided further evidence for human-to-human transmission and airborne transmission within a certain area. Recently, several studies 29 have confirmed that SARS-CoV-2 could also be detected in the gastrointestinal tract, saliva or urine, and proposed transmission by way of the digestive tract. The findings could provide useful evidence for curbing the rapid spread of the disease around the world. The severe patients with COVID-19 infection usually presented with low fever (temperature <38.5°C), dry cough and muscle soreness whereas gastrointestinal symptoms were rare, and 51.7% of the patients had at least 1 underlying disease, suggesting that the tropism of the virus was different from that of SARS-CoV, MERS-CoV and influenza. [30] [31] [32] For example, the symptoms of diarrhea occurred in only 6.7% of patients with COVID-19 infection, significantly less than that in SARS-CoV (38.4%) 32 and MERS-CoV (26%) 30 infection. In addition, Yang Y et al 19 demonstrated in their study that high fever (temperature ≥39°C), cough and sputum production at onset were the most common symptoms among patients with influenza A virus infection. The APACHE II score on admission were not high, and the illness progressed slowly, and ARDS appeared in 15% of the patients and secondary bacterial or fungal infections occurred in 6.7% of the patients, indicating a low fatality rate of the disease. Based on some published studies with a large sample and national official statistics, the cumulative mortality rate was 5.51% in China out of 84,237 confirmed cases as of April 20, 2020, lower than that of SARS-CoV, MERS-CoV and influenza. 6, 11, 29 Most patients had normal or low white blood cell count, low lymphocyte count, and less than 0.5 ng/mL of procalcitonin level. It also caused elevated levels of liver enzymes and troponin T. Lung imaging in most patients showed bilateral ground-glass lesions. These laboratory and radiological characteristics were similar to those of some recently published studies. 14, 29 Patients with COVID-19 infection should also be followed up, in accordance with WHO guidelines for the early initiation of antiviral therapy for patients with influenza. 33 Due to the long incubation period of the disease, pneumonia patients with suspected COVID-19 infection could be given empirical antiviral treatment until COVID-19 infection was ruled out. 19 All patients in this study were treated with antiviral drugs, including abidor, lopinavir and ritonavir, aerosol inhalation of interferon, ribavirin and oseltamivir. The mean course of antiviral was 10.9 § 4.2 days. The protocol on antiviral drugs was based on the recommendation of the Diagnosis and Treatment of Pneumonia Caused by Novel Coronavirus (Pilot Version 5) 23 issued by the National health and fitness commission of China. We selected appropriate antiviral drugs according to the liver and kidney function of the patients. For example, the use of lopinavir and ritonavir should be avoided if the patient had a previous liver disease or abnormal liver function. Similarly, patients with renal dysfunction should avoid using the ribavirin. In terms of antibiotics, the above guidelines 23 recommended avoiding blind or inappropriate use of antibiotics, especially in combination with broad-spectrum antibiotics. In our cohort, we mainly used a single fluoroquinolone to prevent secondary bacterial infections in severe patients. No significant adverse reactions were observed during antiviral and antibiotic therapy. Referring to the latest seventh edition of the Diagnosis and Treatment of Pneumonia Caused by Novel Coronavirus, 34 above antiviral drugs were still recommended, while antiviral therapy of chloroquine phosphate was also recommended in the latest guidelines. However, the clinical efficacy of these antiviral and antibiotic treatments in patients is needed to be further studied in the future. Early studies have shown that increased serum levels of pro-inflammatory cytokines (e.g., interleukin-1 beta, interferon g, monocyte chemotactic protein 1 and inducible protein 10) in patients with COVID-19 infection were associated with pulmonary inflammatory responses and extensive lung injury. 15 In consideration of the high amount of cytokines and inflammatory storm induced by COVID-19, GCs were frequently used to reduce inflammatory lung injury in patients with severe illness. The guidelines 23,34 also recommended intravenous glucocorticoid therapy in the short term (3-5 days) for patients with an overactive inflammatory response to the body. In our study, 34 patients with COVID-19 infection, which had higher serum levels of interleukin-1 and interleukin-6, were treated with GCs. Four of 34 patients developed secondary infections, but there were no statistically significant differences between the improvement and deterioration subgroups. In our study, the effect of GCs was not significant. Furthermore, low lymphocyte count was found in most patients, nearly half of whom received intravenous immunoglobulin therapy in accordance with the advice of critical care specialists and guidelines, but the incidence of secondary infections was not significantly different between the 2 groups. Further larger sample size studies results are pending to provide more efficient evidence. The lung was an important target organ for COVID-19 viral infection, and severe infection could lead to hypoxemia and respiratory failure, even multiple organ dysfunction syndrome (MODS). The severity of hypoxemia assessed by the PaO 2 /FiO 2 ratio was associated with mortality. Oxygen therapy was an important treatment measure to correct hypoxemia and avoid hypoxemia damage of vital organs. Having a full rest in the early stage may decrease oxygen consumption. In this group of cases, early and active oxygen therapy, including noninvasive mechanical ventilation, high-flow nasal cannula, and prone ventilation, maintaining PaO 2 above 60mmHg, and protecting important organs from hypoxemia were the key to effective treatment. Our univariate analysis and logistic regression analysis demonstrated that early prone ventilation was significantly linked to an improvement of the disease. The mechanism of the improvement while ventilation under prone position reduces might due to the reduction/ homogenization of lung stress/strain. However, higher levels of troponin T, lower lymphocyte count and antiviral therapy with aerosol inhalation of interferon were predictors of disease progression. Therefore, treatment of COVID-19 infection with aerosol inhalation of interferon was not recommended in this study. There were also significantly statistical differences in the application of noninvasive mechanical ventilation between the improvement and deterioration subgroups. It could be explained by the fact that most patients with disease progression received the therapy of noninvasive mechanical ventilation, but noninvasive mechanical ventilation did not improve the prognosis of severe patients. We hope that our findings can provide some reference experience and theoretical basis for the treatment of severe cases of COVID-19 in the global community. Our study has some limitations. First, as an early report on a novel human infectious disease, this study only collected data of severe patients from 12 hospitals in Jiangsu Province, China, and the sample size was limited. Second, most of the patients still under hospitalization, the comparison between different prognostic subgroups might be biased. Moreover, it was likely that some patients did not receive confirmed diagnosis and/ or systemic treatment leading to missing data. Finally, this is a retrospective study. We referred to internal and existing international guidelines for the diagnosis and treatment of COVID-19 infections. 23, 35 The data in this study permit a preliminary guidance of optimal management for critical patients with SARS-CoV-2 infection. Further studies are still needed. The mortality rate for patients with severe COVID-19 infection in Jiangsu Province was 0%. The BMI of these patients was higher, with an average of 25 kg/ m 2 . It could spread rapidly by human-to-human transmission and airborne transmission within a certain area, with a mean incubation period of 7.7 days. More than half of severe cases had at least one underlying disease, and low fever and dry cough were the most common symptoms. ARDS appeared in 15% patients. Antiviral therapy with aerosol inhalation of interferon was not recommended. The higher levels of troponin T and lower lymphocyte count were predictors of disease progression. While noninvasive mechanical ventilation did not improve the prognosis of patients, further analysis showed early prone ventilation appeared to be the effective approach to the treatment of COVID-19 pneumonia. WW and CQ came up with the idea and design of the study, had full access to all data in the study and were responsible for the integrity and accuracy of the data. LL, HX, LA, ZH, GQ, SY, LJ, XX, LK and DY collected the epidemiological and clinical data. ZW contributed to the statistical analysis of the data. ZY and SF contributed to finish the first draft of the article. HM and YY contributed to further polish and revise the manuscript. All authors participated in the analysis or interpretation of the data, and reviewed and approved the final version. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan, China. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases The novel coronavirus originating in Wuhan, China: challenges for Global Health Governance Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin A novel coronavirus outbreak of global health concern National Health Commission of the People's Republic of China Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam Transmission of 2019-nCoV infection from an asymptomatic contact in Germany First case of 2019 novel coronavirus in the United States Novel coronavirus: Australian GPs raise concerns about shortage of face masks Novel Coronavirus (2019-nCoV) situation reports A novel coronavirus from patients with pneumonia in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Clinical features of patients infected with 2019 novel coronavirus in Wuhan Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Clinical features of patients infected with 2019 novel coronavirus in Wuhan Novel avian-origin influenza A (H7N9) in critically ill patients in China* APACHE II−a severity of disease classification system Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Diagnosis and Treatment of pneumonia caused by novel coronavirus (Pilot Version 5) Interobserver Reliability of the Berlin ARDS Definition and Strategies to Improve the Reliability of ARDS Diagnosis Acute respiratory distress syndrome: the Berlin Definition Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome Influenza-associated hospitalizations in the United States Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection Avian influenza A (H5N1) infection in humans Diagnosis and treatment of pneumonia caused by novel coronavirus (Pilot Version 7). Clinical Education of General Practice Diagnosis and treatment of adults with communityacquired pneumonia Funding: No specific funding was required to this study. Declaration of Competing Interest: The authors declare no financial conflicts of interest. The first two authors We acknowledge all the medical workers involved in the diagnosis and treatment of the patients; we thank the National Health Commission of China for coordinating the collection of data for patients with COVID-19 infection.